Skip to Main Content

Hello, everyone, and how are you this morning? We are doing just fine, thank you, courtesy of a warm and shiny sun enveloping the leafy Pharmalot campus. Our short people have left for their destinations, our official mascot has tired himself out and is now snoozing in a corner, and we are left with a beckoning coffee pot that is waiting to be fired up. And so, on with the show. Here are a few tidbits to help on your journey. We hope your day is productive and also meaningful. Why not add a little zen now and then? Good luck and keep in touch. …

The Food and Drug Administration approved a medicine from Jacobus Pharmaceuticals, a small, family-run company, for treating a neuromuscular disorder called Lambert-Eaton myasthenic syndrome, or LEMS, for children ages 6 to 17, STAT reports. The move potentially adds unforeseen competition for Catalyst Pharmaceuticals (CPRX), which last December won an FDA endorsement to market a treatment for adults. The approval adds an unexpected twist to a simmering controversy over a rare disease drug that briefly became a poster child for high-priced medicines.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!